Depletion of Cultivatable Gut Microbiota by Broad-Spectrum Antibiotic Pretreatment Worsens Outcome After Murine Stroke

Stroke

Volumn 47, Issue 5, 2016, Pages 1354-1363

  Winek, Katarzyna ^a   Engel, Odilo ^a   Koduah, Priscilla ^a   Heimesaat, Markus M ^a   Fischer, André ^a   Bereswill, Stefan ^a   Dames, Claudia ^a   Kershaw, Olivia ^b   Gruber, Achim D ^b   Curato, Caterina ^a,c,e   Oyama, Naoki ^a   Meisel, Christian ^a   Meisel, Andreas ^a   Dirnagl, Ulrich ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

animal model; antibiotic; brain gut microbiota axis; ischemic stroke; microbiota depletion

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; IMIPENEM; METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DEPLETION; EXPERIMENTAL STROKE; FEMALE; FLOW CYTOMETRY; FOCAL CEREBRAL ISCHEMIA; GENERAL CONDITION DETERIORATION; IMMUNE DEFICIENCY; INTESTINE FLORA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; MURINE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PHENOTYPE; PREMEDICATION; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; C57BL MOUSE; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; DRUG EFFECTS; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; GASTROINTESTINAL MICROBIOME; INFARCTION, MIDDLE CEREBRAL ARTERY; MICE; MICE, INBRED C57BL; STROKE;

EID: 84964047906     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011800     Document Type: Article

References (41)

1. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol. 2011;11:110. doi: 10.1186/1471-2377-11-110.
2. Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2010;9:105-118. doi: 10.1016/S1474-4422(09)70266-2.
3. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A. 2002;99:15451-15455. doi: 10.1073/pnas.202604299.
4. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718-15723. doi: 10.1073/pnas.0407076101.
5. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability-a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189. doi: 10.1186/s12876-014-0189-7.
6. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4:478-485. doi: 10.1038/nri1373.
7. Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Tóth M, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6:263ra158. doi: 10.1126/scitranslmed.3009759.
8. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780-13785. doi: 10.1073/pnas.0706625104.
9. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008;455:1109-1113. doi: 10.1038/nature07336.
10. Hansen AK, Ling F, Kaas A, Funda DP, Farlov H, Buschard K. Diabetes preventive gluten-free diet decreases the number of caecal bacteria in non-obese diabetic mice. Diabetes Metab Res Rev. 2006;22:220-225. doi: 10.1002/dmrr.609.
11. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5:e9085. doi: 10.1371/journal.pone.0009085.
12. Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun. 2014;38:1-12. doi: 10.1016/j. bbi.2013.12.015.
13. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451-1463. doi: 10.1016/j.cell.2013.11.024.
14. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci. 2005;6:775-786. doi: 10.1038/nrn1765.
15. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke. 2007;38(2 suppl):770-773. doi: 10.1161/01. STR.0000251441.89665.bc.
16. Chamorro Á, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol. 2012;8:401-410. doi: 10.1038/nrneurol.2012.98.
17. Caso JR, Hurtado O, Pereira MP, García-Bueno B, Menchén L, Alou L, et al. Colonic bacterial translocation as a possible factor in stress-worsening experimental stroke outcome. Am J Physiol Regul Integr Comp Physiol. 2009;296:R979-R985. doi: 10.1152/ajpregu.90825.2008.
18. Tascilar N, Irkorucu O, Tascilar O, Comert F, Eroglu O, Bahadir B, et al. Bacterial translocation in experimental stroke: what happens to the gut barrier? Bratisl Lek Listy. 2010;111:194-199.
19. Chamorro A, Amaro S, Vargas M, Obach V, Cervera A, Gómez-Choco M, et al. Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci. 2007;252:29-35. doi: 10.1016/j.jns.2006.10.001.
20. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6:306-314. doi: 10.1038/nrgastro.2009.35.
21. Heimesaat MM, Bereswill S, Fischer A, Fuchs D, Struck D, Niebergall J, et al. Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii. J Immunol. 2006;177:8785-8795.
22. Sommer F, Bäckhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol. 2013;11:227-238. doi: 10.1038/nrmicro2974.
23. Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965-977. doi: 10.1038/nn.4030.
24. Bereswill S, Fischer A, Plickert R, Haag LM, Otto B, Kühl AA, et al. Novel murine infection models provide deep insights into the "ménage à trois" of Campylobacter jejuni, microbiota and host innate immunity. PLoS One. 2011;6:e20953. doi: 10.1371/journal.pone.0020953.
25. Dirnagl U; Members of the MCAO-SOP Group. Standard operating procedures (SOP) in experimental stroke research: SOP for middle cerebral artery occlusion in the mouse. Nature Precedings. Acessed October 13, 2015. doi: 10.1038/npre.2010.3492.2.
26. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim. 1981;15:57-59.
27. Faul F, Erdfelder E, Lang AG, Buchner A. G∗Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-191.
28. Tauber SC, Nau R. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol. 2008;1:68-79.
29. Schubert S, Andresen BH, Bähr V, Fischer L, Stamp R, Stricker G, et al. The immunomodulatory effects of antibiotics: in vitro and ex vivo investigations of 21 substances by means of the lymphocyte transformation test. Zentralbl Bakteriol. 1996;284:402-438.
30. Stock ML, Fiedler KJ, Acharya S, Lange JK, Mlynarczyk GS, Anderson SJ, et al. Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities. Neuropharmacology. 2013;73:174-182. doi: 10.1016/j.neuropharm.2013.04.059.
31. Lu JY, Sadri N, Schneider RJ. Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev. 2006;20:3174-3184. doi: 10.1101/gad.1467606.
32. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546. doi: 10.1038/nprot.2007.41.
33. Xu Z, Knight R. Dietary effects on human gut microbiome diversity. Br J Nutr. 2015;113(suppl):S1-S5. doi: 10.1017/S0007114514004127.
34. Schulte-Herbrüggen O, Quarcoo D, Meisel A, Meisel C. Differential affection of intestinal immune cell populations after cerebral ischemia in mice. Neuroimmunomodulation. 2009;16:213-218. doi: 10.1159/000205514.
35. Swidsinski A, Loening-Baucke V, Krüger M, Kirsch S. Central nervous system and the colonic bioreactor: analysis of colonic microbiota in patients with stroke unravels unknown mechanisms of the host defense after brain injury. Intest Res. 2012;10:332-342.
36. Hayakawa M, Asahara T, Henzan N, Murakami H, Yamamoto H, Mukai N, et al. Dramatic changes of the gut flora immediately after severe and sudden insults. Dig Dis Sci. 2011;56:2361-2365. doi: 10.1007/s10620-011-1649-3.
37. Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. doi: 10.1038/ncomms2266.
38. Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14:685-690. doi: 10.1038/ni.2608.
39. Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, et al. Strokeinduced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198:725-736. doi: 10.1084/jem.20021098.
40. Reber SO, Peters S, Slattery DA, Hofmann C, Schölmerich J, Neumann ID, et al. Mucosal immunosuppression and epithelial barrier defects are key events in murine psychosocial stress-induced colitis. Brain Behav Immun. 2011;25:1153-1161. doi: 10.1016/j.bbi.2011.03.004.
41. Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJ, et al; PASS investigators. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. Lancet. 2015;385:1519-1526. doi: 10.1016/S0140-6736(14)62456-9.